Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-02-21
- Target Recruit Count
- 236
- Registration Number
- NCT04761952
Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 153
- Registration Number
- NCT04734678
- Locations
- 🇪🇬
Teachers Hospital, Cairo, Please Select, Egypt
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Biomarkers to Predict and Monitor Response to Infliximab
- Conditions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04655729
- Locations
- 🇺🇸
MassGeneral for Children, Boston, Massachusetts, United States
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Immune Modulators for Treating COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Daniel Benjamin
- Target Recruit Count
- 1971
- Registration Number
- NCT04593940
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 50
- Registration Number
- NCT04564001
Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Children's Hospital of Fudan University
- Registration Number
- NCT04535518
- Locations
- 🇨🇳
Shanghai Children's Hospital, Shanghai, China
🇨🇳Shanghai Children's Medical Center, Shanghai, China
🇨🇳Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT04425538
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04407247
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.